Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Zero Tariff On Anticancer Drugs To China, Will MNCs Sing Hymn?

Executive Summary

Commonly-prescribed medicines, especially imported anticancer drugs, will potentially see zero tariffs in China, although this may be a symbolic sign rather than a substantive move to improve market access for highly-priced products, some say.

You may also be interested in...



China Zero Tariffs For Cancer Drugs Precede High-Stakes Trade Talks

China is opening up its domestic pharma market with an import duty exemption on 28 drugs including anticancers, effective May. The duty cuts came ahead of the latest trade talks between the US and China, though Chinese officials have underscored that countries like India could also stand to gain.

China Vs Cancer: An Infographic Snapshot

Cancer cases are rising in China, with larger increases for certain types including thyroid and pancreatic. To combat the rising tide, the government will implement zero tariffs on imported anticancer drugs  from May.

China Talks Up AI, Big Data, Cancer Care But Approval, Coverage Huddles Persist

Leveraging the internet and big data to improve healthcare, regulatory efficiency and cancer treatment are among the priorities singled out by the Chinese Premier at the annual National People's Congress meeting. Some delegates say drug approval and coverage challenges remain, while industry observers point to commercial insurance as a solution to drive the specialty market such as cancer care.

Topics

UsernamePublicRestriction

Register

PS122748

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel